Next-Generation Sequencing (NGS)

Every cell carries a long instruction manual written in DNA, and cancers grow because of specific spelling mistakes in that manual. Older tests could read only one or a few genes at a time, which was slow and limited. Next-generation sequencing changed this by reading millions of fragments of DNA or RNA in parallel, so a laboratory can examine hundreds of genes, or even the whole genome, from a single sample. In practice this means a tumour can be profiled in depth to find the mutations, fusions and other changes that matter, rather than testing one suspicion at a time. The breadth and speed of NGS are what make modern precision oncology possible, turning a tissue or blood sample into a detailed genetic map of the disease.

The process begins with a sample, most often a small piece of tumour tissue taken at a biopsy or surgery, or a tube of blood when a liquid sample is used. In the laboratory, the genetic material is extracted and prepared, then loaded onto a sequencing machine that reads the code of countless fragments at the same time. Powerful computers and specialised software then assemble these readings, compare them against reference sequences, and flag the meaningful changes while filtering out background noise. Trained molecular pathologists and scientists review the findings and produce a report that explains which alterations were found and what they may mean for treatment. The whole pathway, from sample to interpreted report, usually takes one to a few weeks, depending on how broad the test is.

In cancer care, NGS guides targeted therapy and immunotherapy by identifying the genetic changes a particular drug is designed to act on, helping the team choose treatments that fit the individual tumour rather than relying on averages. It supports molecular tumour boards, where a panel of specialists reviews a patient's genomic profile alongside their clinical picture to recommend the best options, including suitable clinical trials. It is also used to assess inherited cancer risk by testing for changes that run in families, which can inform both treatment and the care of relatives. Beyond solid tumours, sequencing helps characterise blood cancers and can monitor how a disease is responding over time. In each case the aim is the same: to replace guesswork with precise, evidence-based decisions.

The central benefit of next-generation sequencing is personalisation. By revealing the genetic drivers of a specific cancer, it helps match each patient to the therapies most likely to help and to spare them treatments unlikely to work, which can improve outcomes and avoid unnecessary side effects. Testing many genes at once from a single sample is faster and uses less tissue than running many separate tests, and it can uncover unexpected but treatable changes that narrower testing would miss. It opens the door to clinical trials and newer targeted drugs that are chosen by genetic profile. For patients and families, it can also clarify inherited risk and guide screening. Taken together, these advantages make comprehensive genomic testing a cornerstone of modern, individualised cancer care.